Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC+MIND
NCT07464886Phase 3Recruiting
- Sponsor
- University of Cincinnati
- Start
- Feb 2026
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acetylcysteine in major depressive disorder (MDD), sponsored by University of Cincinnati. Started Feb 2026; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07464886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464886.